{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:46:59Z","timestamp":1790704019134,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"27","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":190,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009886","name":"Puglia Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.vaccine.2023.04.047","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T04:59:12Z","timestamp":1682744352000},"page":"4057-4063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prevalence of poliovirus neutralizing antibodies in Italian population: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"41","author":[{"given":"Silvio","family":"Tafuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eustachio","family":"Cuscianna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.04.047_b0005","unstructured":"WHO. Poliomyelitis. Key facts. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/poliomyelitis. Last accessed on 24 November 2022."},{"key":"10.1016\/j.vaccine.2023.04.047_b0010","unstructured":"CDC. What is Polio. Available from: https:\/\/www.cdc.gov\/polio\/what-is-polio\/hcp.html#poliovirus. Last accessed on 25 November 2022."},{"key":"10.1016\/j.vaccine.2023.04.047_b0015","unstructured":"WHO. Biologicals. Oral polio vaccine (OPV). Available from: https:\/\/www.who.int\/biologicals\/areas\/vaccines\/polio\/opv\/en\/. Last accessed on 27 November 2022."},{"key":"10.1016\/j.vaccine.2023.04.047_b0020","unstructured":"CDC. Pink book. Epidemiology and Prevention of Vaccine-Preventable Diseases. Poliomyelitis. Available from: https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/polio.html#vaccines. Last accessed on 25 November 2022."},{"key":"10.1016\/j.vaccine.2023.04.047_b0025","unstructured":"CDC. Vaccines and Preventable Diseases. Vaccine-derived Poliovirus. Available from: https:\/\/www.cdc.gov\/vaccines\/vpd\/polio\/hcp\/vaccine-derived-poliovirus-faq.html. Last accessed on 30 November 2022."},{"key":"10.1016\/j.vaccine.2023.04.047_b0030","unstructured":"CDC. Who We Are: CDC and the Global Polio Eradication Initiative. Available from: https:\/\/www.cdc.gov\/polio\/who\/index.htm. Last accessed on 28 October 2020."},{"key":"10.1016\/j.vaccine.2023.04.047_b0035","doi-asserted-by":"crossref","unstructured":"Bandyopadhyay AS, Gast C, Rivera L, et al. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. Lancet Infect Dis 2020. Published Online October 23, 2020.","DOI":"10.1016\/S1473-3099(20)30555-7"},{"key":"10.1016\/j.vaccine.2023.04.047_b0040","unstructured":"Global Polio Eradication Initiative. Wild poliovirus list. List of wild poliovirus by country and year. Available from: http:\/\/polioeradication.org\/polio-today\/polio-now\/wild-poliovirus-list. Last accessed on 26 November 2022."},{"key":"10.1016\/j.vaccine.2023.04.047_b0045","unstructured":"WHO. Wild poliovirus type 1 (WPV1) \u2013 Mozambique. Available on: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON395. Last accessed on February 14, 2023."},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.047_b0050","article-title":"Public Health History Corner History of polio vaccination in Italy","volume":"7","author":"Crovari","year":"2010","journal-title":"IJPH \u2013 Year 8"},{"key":"10.1016\/j.vaccine.2023.04.047_b0055","unstructured":"Italian Ministry of Health. Decree Law 7 June 2017, n. 73, Urgent provisions on vaccination prevention, as amended by the conversion law July 31, 2017]. Available from: http:\/\/www.trovanorme.salute.gov.it\/norme\/dettaglioAtto?id=60201. Last accessed on 23 November 2022."},{"key":"10.1016\/j.vaccine.2023.04.047_b0060","unstructured":"Italian Ministry of Health. Vaccination in Italy. Vaccine coverage in Italy. Poliomyelitis. Available from: https:\/\/www.epicentro.iss.it\/vaccini\/dati_Ita. Last accessed on 31 November 2022."},{"key":"10.1016\/j.vaccine.2023.04.047_b0065","unstructured":"WHO European Region. Certification of the Region\u2019s polio-free status in 2002. Available from: https:\/\/www.euro.who.int\/en\/health-topics\/communicable-diseases\/poliomyelitis\/activities\/certification-and-maintenance-of-polio-free-status-in-the-european-region\/european-regional-commission-for-the-certification-of-poliomyelitis-eradication\/certification-of-the-regions-polio-free-status-in-2002. Last accessed on 21 November 2022."},{"key":"10.1016\/j.vaccine.2023.04.047_b0070","unstructured":"CDC. Vaccines and Preventable Diseases. Polio Vaccine Effectiveness and Duration of Protection. Available from: https:\/\/www.cdc.gov\/vaccines\/vpd\/polio\/hcp\/effectiveness-duration-protection.html. Last accessed on 29 November 2022."},{"key":"10.1016\/j.vaccine.2023.04.047_b0075","unstructured":"The Immunisation Advisory Centre. Efficacy and effectiveness. Available from: https:\/\/www.immune.org.nz\/vaccines\/efficiency-effectiveness. Last accessed on 24 November 2022."},{"issue":"378","key":"10.1016\/j.vaccine.2023.04.047_b0080","article-title":"Polio emergency declared in New York State over virus found in wastewater","volume":"12","author":"Tanne","year":"2022","journal-title":"BMJ"},{"issue":"372","key":"10.1016\/j.vaccine.2023.04.047_b0085","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"29","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.04.047_b0090","series-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells","year":"2014"},{"issue":"8","key":"10.1016\/j.vaccine.2023.04.047_b0095","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3390\/vaccines10081329","article-title":"Long-Term Immunogenicity of Inactivated and Oral Polio Vaccines: An Italian Retrospective Cohort Study","volume":"10","author":"Larocca","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"22","key":"10.1016\/j.vaccine.2023.04.047_b0100","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.vaccine.2021.04.005","article-title":"Long-term persistence of poliovirus neutralizing antibodies in the era of polio elimination: An Italian retrospective cohort study","volume":"39","author":"Bianchi","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.047_b0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/biomedicines9010087","article-title":"Immunogenicity of Viral Vaccines in the Italian Military","volume":"9","author":"Ferlito","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.047_b0110","doi-asserted-by":"crossref","first-page":"e2020014","DOI":"10.4084\/mjhid.2020.014","article-title":"The Impact of Chemotherapy after Pediatric Malignancy on Humoral Immunity to Vaccine-Preventable Diseases","volume":"12","author":"Garonzi","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.047_b0115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/21645515.2018.1547608","article-title":"Assessment of seroprevalence against poliovirus among Italian adolescents and adults","volume":"15","author":"Lupi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.vaccine.2023.04.047_b0120","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1080\/21645515.2018.1475812","article-title":"Is Italian population protected from Poliovirus? Results of a seroprevalence survey in Florence","volume":"14","author":"Giammanco","year":"2018","journal-title":"Italy Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2023.04.047_b0125","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1128\/CVI.00054-12","article-title":"Seroepidemiology of polioviruses among university students in northern Italy","volume":"19","author":"Baldo","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"39","key":"10.1016\/j.vaccine.2023.04.047_b0130","doi-asserted-by":"crossref","first-page":"e2019354","DOI":"10.1590\/1984-0462\/2021\/39\/2019354","article-title":"Prevalence of neutralizing antibodies against poliovirus 1, 2, and 3 in healthcare professionals aged 20\u201350 years","volume":"3","author":"Moraes","year":"2021","journal-title":"Rev Paul Pediatr"},{"issue":"12","key":"10.1016\/j.vaccine.2023.04.047_b0135","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.vaccine.2017.02.018","article-title":"Immunity against vaccine-preventable diseases in Finnish pediatric healthcare workers in 2015","volume":"35","author":"Koivisto","year":"2017","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2023.04.047_b0140","doi-asserted-by":"crossref","first-page":"20705","DOI":"10.2807\/1560-7917.ES2014.19.7.20705","article-title":"Immunity against poliomyelitis in the Netherlands, assessed in 2006 to 2007: the importance of completing a vaccination series","volume":"19","author":"van der Maas","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2023.04.047_b0145","first-page":"1","article-title":"Long time persistence of antibodies against Mumps in fully MMR immunized young adults: an Italian retrospective cohort study","volume":"18","author":"Bianchi","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.vaccine.2023.04.047_b0150","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3390\/vaccines10101633","article-title":"Vaccination Offer during the Occupational Health Surveillance Program for Healthcare Workers and Suitability to Work: An Italian Retrospective Cohort Study","volume":"10","author":"Bianchi","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"10.1016\/j.vaccine.2023.04.047_b0155","article-title":"Prevalence and management of rubella susceptibility in healthcare workers in Italy: A systematic review and meta-analysis","volume":"7","author":"Bianchi","year":"2022","journal-title":"Vaccine X"},{"issue":"23","key":"10.1016\/j.vaccine.2023.04.047_b0160","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.vaccine.2022.04.016","article-title":"Sex and age as determinants of the seroprevalence of anti-measles IgG among European healthcare workers: A systematic review and meta-analysis","volume":"40","author":"Bianchi","year":"2022","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2023.04.047_b0165","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1080\/21645515.2020.1871296","article-title":"Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study","volume":"17","author":"Bianchi","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.vaccine.2023.04.047_b0170","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/vaccines9101143","article-title":"Control Room Working Group. BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study","volume":"9","author":"Bianchi","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"4 Suppl 1","key":"10.1016\/j.vaccine.2023.04.047_b0175","first-page":"76","article-title":"Migrant health: the Apulian model","volume":"39","author":"Germinario","year":"2015","journal-title":"Epidemiol Prev"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.047_b0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1708-8305.2011.00571.x","article-title":"Surveillance of poliovirus circulation among refugees in Italy, 2008\u20132011","volume":"19","author":"Tafuri","year":"2012","journal-title":"J Travel Med"},{"issue":"36","key":"10.1016\/j.vaccine.2023.04.047_b0185","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1016\/j.vaccine.2019.06.068","article-title":"Venice survey working group. Immunisation of migrants in EU\/EEA countries: Policies and practices","volume":"37","author":"Giambi","year":"2019","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2023.04.047_b0190","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1016\/j.vaccine.2013.06.106","article-title":"Population immunity to polioviruses in the context of a large-scale wild poliovirus type 1 outbreak in Tajikistan, 2010","volume":"31","author":"Khetsuriani","year":"2013","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2023.04.047_b0195","first-page":"107","article-title":"The polio epidemic in The Netherlands, 1992\/1993","volume":"21","author":"van Wijngaarden","year":"1993","journal-title":"Public Health Rev"},{"issue":"16","key":"10.1016\/j.vaccine.2023.04.047_b0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12879-016-1587-y","article-title":"Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis","volume":"10","author":"Foiadelli","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.047_b0205","first-page":"47","article-title":"Polio control after certification: major issues outstanding","volume":"82","author":"Fine","year":"2004","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2023.04.047_b0210","unstructured":"Italian Ministry of Health. Acute flaccid paralysis surveillance. Available from: http:\/\/www.salute.gov.it\/portale\/malattieInfettive\/dettaglioContenutiMalattieInfettive.jsp?lingua=italiano&id=820&area=Malattie%20infettive&menu=sorveglianza#:\u223c:text=Il%20sistema%20di%20sorveglianza%20delle%20Paralisi%20Flaccide%20acute%20(PFA)%2C,mostrano%20sintomatologia%20identica%20alla%20polio. Last accessed on 01 November 2022."},{"key":"10.1016\/j.vaccine.2023.04.047_b0215","unstructured":"Italian Ministry of Health. National Plan of Vaccinal Prevention (PNPV) 2017-2019. Available from: http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2571_allegato.pdf. Last accessed on 03 November 2022."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T07:38:02Z","timestamp":1718437082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23004607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":43,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0264410X23004607"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of poliovirus neutralizing antibodies in Italian population: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}